Literature DB >> 8149355

Molecular, functional and biochemical characteristics of the dopamine transporter: regional differences and clinical relevance.

A Hitri1, Y L Hurd, R J Wyatt, S I Deutsch.   

Abstract

The carrier molecule that transports dopamine (DA) across the synaptic membrane is known as the dopamine transporter (DAT). Depending on the ionic conditions, DAT may function as a mediator of both the inward directed DA transport known as the "reuptake" and the outward directed DA transport known as the "release." The functional significance of DAT is in the regulation of DA neurotransmission by terminating the action of DA in the synapse via reuptake. With use of DAT binding as a presynaptic marker to measure altered DA innervation, abnormalities of the DAT binding have been demonstrated in idiopathic Parkinson's disease, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity, and progressive supranuclear palsy. Moreover, the identification of DAT as the neuronal element that mediates the addictive properties of cocaine highlights its significance in cocaine addiction. Cocaine binding in the brain is heterogeneous, and there is an uneven distribution of the high- and low-affinity binding sites across the anatomical regions. Regional differences in ligand binding are observed by using both [3H]cocaine and the diphenyl-substituted piperazine derivatives known as the "GBR series" of ligands. The identification of compounds that inhibit the binding of medications for cocaine abuse. Furthermore, clarification of the various binding domains that may be relevant to transporter function in human neuropsychiatric disorders may lead to the development of new medications for schizophrenia, Tourette's disease, and drug addiction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8149355     DOI: 10.1097/00002826-199402000-00001

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  18 in total

1.  Identification of an intronic cis-acting element in the human dopamine transporter gene.

Authors:  Ying Zhao; Yanhong Zhou; Nian Xiong; Zhicheng Lin
Journal:  Mol Biol Rep       Date:  2011-12-13       Impact factor: 2.316

Review 2.  Metabolomics of Methylphenidate and Ethylphenidate: Implications in Pharmacological and Toxicological Effects.

Authors:  Ricardo Jorge Dinis-Oliveira
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-02       Impact factor: 2.441

3.  Absence of linkage for schizophrenia on the short arm of chromosome 5 in multiplex Canadian families.

Authors:  N King; A S Bassett; W G Honer; M Masellis; J L Kennedy
Journal:  Am J Med Genet       Date:  1997-09-19

4.  Immunogold localization of the dopamine transporter: an ultrastructural study of the rat ventral tegmental area.

Authors:  M J Nirenberg; J Chan; R A Vaughan; G R Uhl; M J Kuhar; V M Pickel
Journal:  J Neurosci       Date:  1997-07-15       Impact factor: 6.167

Review 5.  Evolution of stimulants to treat ADHD: transdermal methylphenidate.

Authors:  Kennerly S Patrick; Arthur B Straughn; Jeb S Perkins; Mario A González
Journal:  Hum Psychopharmacol       Date:  2009-01       Impact factor: 1.672

6.  Foetal nigral cell suspension grafts influence dopamine release in the non-grafted side in the 6-hydroxydopamine rat model of Parkinson's disease: in vivo voltammetric data.

Authors:  C D Earl; T Reum; J X Xie; J Sautter; A Kupsch; W H Oertel; R Morgenstern
Journal:  Exp Brain Res       Date:  1996-04       Impact factor: 1.972

7.  Basal ganglia surface morphology and the effects of stimulant medications in youth with attention deficit hyperactivity disorder.

Authors:  Loren J Sobel; Ravi Bansal; Tiago V Maia; Juan Sanchez; Luigi Mazzone; Kathleen Durkin; Jun Liu; Xuejun Hao; Iliyan Ivanov; Ann Miller; Laurence L Greenhill; Bradley S Peterson
Journal:  Am J Psychiatry       Date:  2010-07-01       Impact factor: 18.112

Review 8.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

9.  Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study.

Authors:  N Drandarevski; A Marburger; D Walther; T Reum; G Uh; R Morgenstern
Journal:  J Neural Transm (Vienna)       Date:  2001       Impact factor: 3.575

10.  miR-137 and miR-491 Negatively Regulate Dopamine Transporter Expression and Function in Neural Cells.

Authors:  Xiaojian Jia; Feng Wang; Ying Han; Xuewen Geng; Minghua Li; Yu Shi; Lin Lu; Yun Chen
Journal:  Neurosci Bull       Date:  2016-09-15       Impact factor: 5.203

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.